• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Natera Inc. (Amendment)

    2/14/24 4:06:56 PM ET
    $NTRA
    Medical Specialities
    Health Care
    Get the next $NTRA alert in real time by email
    SC 13G/A 1 d117525dsc13ga.htm NATERA, INC. Natera, Inc.

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 3)*

     

     

    Natera, Inc.

    (Name of Issuer)

    Common Stock

    (Title of Class of Securities)

    632307104

    (CUSIP Number)

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 632307104

     

    1.      

    Names of Reporting Persons

     

    Alger Associates, Inc. 13-3017981

    2.      

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)  ☐        (b)  ☐

    3.      

    SEC Use Only

     

        

    4.      

    Citizenship or Place of Organization

     

    New York

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

        5.       

    Sole Voting Power

     

    6,582,312

        6.       

    Shared Voting Power

     

    0

        7.       

    Sole Dispositive Power

     

    7,076,157

        8.       

    Shared Dispositive Power

     

    0

    9.      

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    7,076,157

    10.      

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

    ☐

    11.      

    Percent of Class Represented by Amount in Row (9)

     

    5.9%

    12.      

    Type of Reporting Person (See Instructions)

     

    HC

     

    2


    Item 1.

         
       (a)    Name of Issuer
         

    Natera, Inc.

       (b)   

    Address of Issuer’s Principal Executive Offices

    13011 McCallen Pass

    Building A, Suite 100

    Austin, TX 78753

    Item 2.

         
       (a)    Name of Person Filing
         

    Alger Associates, Inc.

       (b)    Address of Principal Business Office or, if none, Residence
         

    100 Pearl Street, 27th Floor, New York, NY 10004

       (c)    Citizenship
         

    New York

       (d)    Title of Class of Securities
         

    Common Stock

       (e)    CUSIP Number
         

    632307104

    Item 3.

       If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
      

    (a)

       ☐   

    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

      

    (b)

       ☐   

    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

      

    (c)

       ☐   

    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

      

    (d)

       ☐   

    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

      

    (e)

       ☐   

    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

      

    (f)

       ☐   

    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

      

    (g)

       ☒   

    A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

      

    (h)

       ☐   

    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

      

    (i)

       ☐    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
      

    (j)

       ☐   

    A non-U.S. institution in accordance with § 240.13d–1(b)(1)(ii)(J);

      

    (k)

       ☐    Group, in accordance with § 240.13d–1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d–1(b)(1)(ii)(J), please specify the type of institution:                                         

     

    3


    Item 4.

    Ownership

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

            (a)   Amount beneficially owned:
     

    7,076,157

     

            (b)   Percent of class:
     

    5.9%

            (c)  

    Number of shares as to which the person has:

     

      (i)        Sole power to vote or to direct the vote
        

    6,582,312

      (ii)        Shared power to vote or to direct the vote
        

    0

      (iii)        Sole power to dispose or to direct the disposition of
        

    7,076,157

      (iv)        Shared power to dispose or to direct the disposition of
        

    0

     

    Item 5.

    Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person

    The securities reported herein are beneficially owned by one or more open-end investment companies or other managed accounts that are investment management clients of Fred Alger Management, LLC (“FAM”), a registered investment adviser, and Weatherbie Capital, LLC (“WC”), a registered investment adviser. Each of FAM and WC is a 100% owned subsidiary of Alger Group Holdings, LLC (“AGH”), a holding company. AGH is a 100% owned subsidiary of Alger Associates, Inc., a holding company.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

    See Exhibit A

     

    Item 8.

    Identification and Classification of Members of the Group

     

    Item 9.

    Notice of Dissolution of Group

     

    Item 10.

    Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

    4


    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    By:

      Alger Associates, Inc.

    By:

     

    /s/ Hal Liebes

    Name:

      Hal Liebes

    Title:

      Secretary

    Date:

      February 14, 2024

     

    5


    Exhibit A

    Subsidiary

    Alger Group Holdings, LLC* — HC

    Fred Alger Management, LLC* — IA

    Weatherbie Capital, LLC — IA

    * Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G.

    Get the next $NTRA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NTRA

    DatePrice TargetRatingAnalyst
    1/7/2026$300.00Buy
    Citigroup
    12/2/2025$265.00Overweight
    Morgan Stanley
    10/27/2025$172.00Underperform → Neutral
    BNP Paribas Exane
    9/22/2025$175.00Equal Weight
    Wells Fargo
    3/13/2025$251.00Outperform
    RBC Capital Mkts
    1/23/2025$200.00Overweight
    Barclays
    6/3/2024$142.00Buy
    Jefferies
    4/8/2024$117.00Buy
    Craig Hallum
    More analyst ratings

    $NTRA
    SEC Filings

    View All

    SEC Form 144 filed by Natera Inc.

    144 - Natera, Inc. (0001604821) (Subject)

    1/2/26 4:13:25 PM ET
    $NTRA
    Medical Specialities
    Health Care

    SEC Form 144 filed by Natera Inc.

    144 - Natera, Inc. (0001604821) (Subject)

    12/12/25 10:07:26 AM ET
    $NTRA
    Medical Specialities
    Health Care

    SEC Form S-3ASR filed by Natera Inc.

    S-3ASR - Natera, Inc. (0001604821) (Filer)

    12/10/25 9:02:55 AM ET
    $NTRA
    Medical Specialities
    Health Care

    $NTRA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Octave Bioscience Expands Leadership Team with Appointment of Kirk Stockwood Senior Vice President, Commercial

    Octave Bioscience, Inc., a commercial stage precision medicine company pioneering biomarker driven solutions for multiple sclerosis, Parkinson's disease and other neurodegenerative diseases today announced the appointment of Kirk Stockwood as Senior Vice President, Commercial. Mr. Stockwood will spearhead Octave's commercial strategy as the company scales operations and expands the reach of its precision neurology platform. Mr. Stockwood brings over 20 years of leadership experience in specialty diagnostics and tools, with a proven track record of commercial scaling within public and private companies. Most recently as Vice President of Sales at Quanterix, he led a global team focused on

    1/8/26 4:01:00 PM ET
    $NTRA
    Medical Specialities
    Health Care

    Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer

    – STELLAR-316 will use Natera's Signatera™ assay to identify MRD-positive patients for trial enrollment and to monitor response to therapy – Exelixis, Inc. (NASDAQ:EXEL) and Natera (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today announced their collaboration on the planned Exelixis-sponsored STELLAR-316 trial. This randomized phase 3 pivotal trial will evaluate zanzalintinib, Exelixis' novel oral kinase inhibitor, with and without an immune checkpoint inhibitor, in patients with resected stage II/III colorectal cancer (CRC). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107329077/en/ Using Nat

    1/7/26 8:00:00 AM ET
    $EXEL
    $NTRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical Specialities

    Natera Presents Updated Analyses From ALTAIR Clinical Trial at ASCO GI

    Study showed a statistically significant disease-free survival (DFS) benefit in all SignateraTM-positive patients following blinded central review Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today announced that new data from the ALTAIR trial will be presented at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI), taking place January 8-10, 2026. A new analysis will be presented from the randomized, double-blind, phase III ALTAIR clinical trial (NCT04457297). ALTAIR examined treatment on molecular recurrence (TOMR) with Trifluridine/Tipiracil (FTD/TPI) in Signatera-positive patients with stage I-IV colorec

    1/5/26 7:25:00 PM ET
    $NTRA
    Medical Specialities
    Health Care

    $NTRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    PRESIDENT, CLINICALDIAGNOSTICS Moshkevich Solomon sold $675,621 worth of shares (2,951 units at $228.95), decreasing direct ownership by 2% to 123,499 units (SEC Form 4)

    4 - Natera, Inc. (0001604821) (Issuer)

    1/6/26 9:05:09 PM ET
    $NTRA
    Medical Specialities
    Health Care

    CO-FOUNDER Sheena Jonathan exercised 39,615 shares at a strike of $9.59, increasing direct ownership by 18% to 262,581 units (SEC Form 4)

    4 - Natera, Inc. (0001604821) (Issuer)

    1/6/26 9:05:11 PM ET
    $NTRA
    Medical Specialities
    Health Care

    CEO AND PRESIDENT Chapman Steven Leonard sold $881,482 worth of shares (3,848 units at $229.08), decreasing direct ownership by 3% to 136,568 units (SEC Form 4)

    4 - Natera, Inc. (0001604821) (Issuer)

    1/6/26 9:05:06 PM ET
    $NTRA
    Medical Specialities
    Health Care

    $NTRA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citigroup initiated coverage on Natera with a new price target

    Citigroup initiated coverage of Natera with a rating of Buy and set a new price target of $300.00

    1/7/26 9:12:45 AM ET
    $NTRA
    Medical Specialities
    Health Care

    Morgan Stanley resumed coverage on Natera with a new price target

    Morgan Stanley resumed coverage of Natera with a rating of Overweight and set a new price target of $265.00

    12/2/25 8:28:19 AM ET
    $NTRA
    Medical Specialities
    Health Care

    Natera upgraded by BNP Paribas Exane with a new price target

    BNP Paribas Exane upgraded Natera from Underperform to Neutral and set a new price target of $172.00

    10/27/25 9:03:32 AM ET
    $NTRA
    Medical Specialities
    Health Care

    $NTRA
    Leadership Updates

    Live Leadership Updates

    View All

    Octave Bioscience Expands Leadership Team with Appointment of Kirk Stockwood Senior Vice President, Commercial

    Octave Bioscience, Inc., a commercial stage precision medicine company pioneering biomarker driven solutions for multiple sclerosis, Parkinson's disease and other neurodegenerative diseases today announced the appointment of Kirk Stockwood as Senior Vice President, Commercial. Mr. Stockwood will spearhead Octave's commercial strategy as the company scales operations and expands the reach of its precision neurology platform. Mr. Stockwood brings over 20 years of leadership experience in specialty diagnostics and tools, with a proven track record of commercial scaling within public and private companies. Most recently as Vice President of Sales at Quanterix, he led a global team focused on

    1/8/26 4:01:00 PM ET
    $NTRA
    Medical Specialities
    Health Care

    Experienced Biotech Executive and Deal Maker Joins Zephyr AI as Chief Business Officer

    Zephyr AI, Inc. ("Zephyr AI"), a company building novel transparent AI to address unmet needs across the full spectrum of precision medicine – from prevention to treatment – to improve patients' lives, today announced the appointment of Eric Lindquist as its new Chief Business Officer. "At Zephyr AI, we have set out to use artificial intelligence and machine learning to bring precision medicine to those suffering from cancer, and our goal is for patients everywhere to be able to find the right treatment, delivered by the right provider, when they need it, enabling them to live healthier and fuller lives," said Grant Verstandig, Co-Founder and Executive Chairman of Zephyr AI. "Eric has bee

    6/5/23 11:06:00 AM ET
    $NTRA
    Medical Specialities
    Health Care

    Natera Appoints Ruth E. Williams-Brinkley to its Board of Directors

    Seasoned healthcare executive with extensive leadership experience in health plans, hospital operations, and physician relations Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA testing, today announced that Ruth E. Williams-Brinkley has been appointed to the Company's board of directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230223005436/en/(Photo: Business Wire) Williams-Brinkley has three decades of healthcare industry experience. She currently serves as president of Kaiser Permanente Health Plan of the Mid-Atlantic States (KPMAS), where she oversees the company's care delivery and health plan operations

    2/23/23 8:05:00 AM ET
    $NTRA
    Medical Specialities
    Health Care

    $NTRA
    Financials

    Live finance-specific insights

    View All

    Natera Acquires Foresight Diagnostics

    Expands Natera's lead in solid tumor MRD, acquiring ultrasensitive phased variant technology with LOD95 of 0.3 parts per million (ppm) and detection below 0.1 ppm1 Cutting-edge IP adds to Natera's portfolio of >500 issued or pending patents Accelerates Natera's expansion into lymphoma, where Foresight has developed a strong clinical position Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, and Foresight Diagnostics, a leader in ultrasensitive molecular residual disease (MRD) detection, today announced that Natera has completed a transaction to acquire Foresight. Foresight is a cancer diagnostics company and CLIA-registered laboratory. The company's ci

    12/5/25 7:00:00 AM ET
    $NTRA
    Medical Specialities
    Health Care

    Natera Reports Third Quarter 2025 Financial Results

    Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today reported its financial results for the third quarter ended September 30, 2025. Recent Financial Highlights Generated total revenues of $592.2 million in the third quarter of 2025, compared to $439.8 million in the third quarter of 2024, an increase of 34.7%. Product revenues grew 35.3% over the same period. Generated a gross margin percentage2 of 64.9% in the third quarter of 2025, compared to a gross margin percentage2 of 61.8% in the third quarter of 2024. Processed approximately 893,600 tests in the third quarter of 2025, compared to approximately 775,800 tests in the third quarter of 2024,

    11/6/25 4:05:00 PM ET
    $NTRA
    Medical Specialities
    Health Care

    Natera to Report its Third Quarter Results on November 6, 2025

    Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will release results for its third quarter ended September 30, 2025, after the market closes on November 6, 2025. Natera will host a conference call and webcast shortly thereafter at 4:30 p.m. ET. Earnings Conference Call Information Event: Natera's Third Quarter 2025 Financial Results Date: November 6, 2025 Time: 4:30 p.m. ET Live Dial-In: 1-888-770-7321 (Domestic)   1-929-201-7107 (International) Conference ID: 7684785 Webcast: https://events.q4inc.com/attendee/822764987

    10/30/25 7:00:00 AM ET
    $NTRA
    Medical Specialities
    Health Care

    $NTRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Natera Inc.

    SC 13G/A - Natera, Inc. (0001604821) (Subject)

    11/14/24 4:02:50 PM ET
    $NTRA
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Natera Inc. (Amendment)

    SC 13G/A - Natera, Inc. (0001604821) (Subject)

    6/7/24 12:07:25 PM ET
    $NTRA
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Natera Inc. (Amendment)

    SC 13G/A - Natera, Inc. (0001604821) (Subject)

    2/14/24 4:06:56 PM ET
    $NTRA
    Medical Specialities
    Health Care